Vol. 2, Issue 3 (2013)
Violation of Cellular and Humoral Immunity in Patients with First Emerged and Progressive Angina
AViktor Lyzogub, Tetyana Zavalskaya, Khaled Ahmad Khalil Abu Sara, Mariya Sayuk
The study involved 67 patients with unstable angina (UA) aged 55 to 69 years - 20 patients with first emerged angina (FEA) and 47 patients with progressive angina (PSA). The control group (CG) consisted of 22 healthy persons. Defining populations and subpopulations of lymphocytes were carried out using monoclonal antibodies. Definition Immunoglobulin’s IgG, IgA, IgM and circulating immune complexes (CIC) in serum blood was performed by the method of Mancini. In patients with FEA and PSA compared with healthy individuals revealed significantly lower levels of lymphocyte populations. In patients with PRS, in contrast to patients with FEA, found significantly higher populations of B lymphocytes (CD22+) healthy individuals. Thus, in patients with severe forms of ischemic heart disease (IHD), coronary circulation destabilization accompanied by an imbalance of populations and subpopulations of lymphocytes manifested inhibition of cellular immunity due to a population of T-lymphocytes (CD3 +) and T-suppressor (CD8 +). In patients with PRS, except the above, found increased activity of cellular immunity by subpopulation of T-helper cells (CD4 +) and a population of B-lymphocytes (CD22 +). Noteworthy is the fact that patients with PRS compared with patients with FEA determined significantly higher values lymphocyte levels, populations of T-lymphocytes (CD3 +), subpopulation of T-helper cells (CD4 +), suggesting a more pronounced inflammatory processes in patients with PRS. Analyzing changes in humeral immunity in patients with FEA and PSA compared with CG, found under significant increase of IgG, circulating immune complexes (CIC). In patients with PRS compared with patients with FEA IgG level was significantly increased 3.2 times. Therefore in violation of the coronary circulation is increased activity of humeral immunity, whereby patients with PSA expressed more than patients FEA.
How to cite this article:
AViktor Lyzogub, Tetyana Zavalskaya, Khaled Ahmad Khalil Abu Sara, Mariya Sayuk. . The Pharma Innovation Journal. 2013; 2(3): 49-51.